San Diego – – October 13, 2026 -- Inhibrx Biosciences (Nasdaq: INBX) will present phase 2 data on both clinical-stage candidates in its pipeline in four sessions at three oncology conferences between Oct. 25 and Nov. 20, 2026.

San Diego – September 11, 2026 -- Inhibrx Biosciences reported that its OX40 agonist INBRX-106, combined with pembrolizumab, produced a 48.3% confirmed objective response rate in first-line head and neck squamous cell carcinoma patients, nearly double the 26.5% seen with pembrolizumab alone.